ARYx Therapeutics, Inc. (NASDAQ: ARYX) announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE